Pfizer Inc
NYSE: PFE
$24.80
-$1.22 (-4.7%)
Closing Price on November 15, 2024
PFE Articles
Two alternative energy companies report March quarter earnings after the closing bell Monday, and three other noteworthy reports are due before Tuesday's opening bell.
Published:
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including Abercrombie & Fitch, Pfizer and Teva Pharmaceutical.
Published:
Thursday's top analyst upgrades and downgrades included Apple, Best Buy, Electronic Arts, FireEye, Match, PayPal, Qualcomm and ViacomCBS.
Published:
These five outstanding stocks are rated Buy, have a least a 4% dividend and offer investors a degree of relative safety. They make sense for growth and income investors while the stock market is...
Published:
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Published:
Myovant shares shot up on Monday after the company announced a new collaboration with Pfizer for its tumor treatment across a couple of indications.
Published:
Wednesday's top analyst upgrades and downgrades included Chipotle Mexican Grill, Etsy, Exxon Mobil, General Electric, Jazz Pharmaceuticals, Microsoft, Nikola, Palo Alto Networks, Pfizer and Twitter.
Published:
BioNTech was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst.
Published:
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
Published:
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Published:
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Published:
Shares of COVID-19 vaccine duo Pfizer and BioNTech made handy gains on Wednesday after they announced their late-stage coronavirus study had concluded.
Published:
Some rather significant changes were made in the Berkshire Hathaway equity portfolio during the third quarter.
Published:
Last Updated:
Moderna reported a 95.4% effectiveness rate for its COVID-19 vaccine. This is the second vaccine to hit more than 90% efficacy in the past week.
Published:
Tuesday's top analyst upgrades and downgrades included AbbVie, Beyond Meat, Biogen, Eli Lilly, Levi Strauss, Nvidia, Pfizer, Plug Power, Raytheon, Square and Wayfair.
Published:
Last Updated: